TR200000415T2 - Prostat kanserinin tedavi edilmesi için birleşimler. - Google Patents

Prostat kanserinin tedavi edilmesi için birleşimler.

Info

Publication number
TR200000415T2
TR200000415T2 TR2000/00415T TR200000415T TR200000415T2 TR 200000415 T2 TR200000415 T2 TR 200000415T2 TR 2000/00415 T TR2000/00415 T TR 2000/00415T TR 200000415 T TR200000415 T TR 200000415T TR 200000415 T2 TR200000415 T2 TR 200000415T2
Authority
TR
Turkey
Prior art keywords
prostate cancer
combinations
treat prostate
tyrosine kinase
kinase inhibitor
Prior art date
Application number
TR2000/00415T
Other languages
English (en)
Inventor
A. Dionne Craig
Isaacs John
L. Vaught Jeffry
Original Assignee
Cephalon Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22000842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200000415(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc. filed Critical Cephalon Inc.
Publication of TR200000415T2 publication Critical patent/TR200000415T2/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Prostat kanserinin, bir indolokarbazol olarak bir tirosin kinaz önleyiciyle ve bir kimyasal hadim etme madesinin birlikte uygulanmasiyla tedavi edilmesi için bir yöntem anlatilir. Bir tirosin kinaz önleyici ve bir kimyasal hadim etme maddesi içeren bir bilesik de ayrica anlatilir.
TR2000/00415T 1997-08-15 1998-08-13 Prostat kanserinin tedavi edilmesi için birleşimler. TR200000415T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5589197P 1997-08-15 1997-08-15

Publications (1)

Publication Number Publication Date
TR200000415T2 true TR200000415T2 (tr) 2000-08-21

Family

ID=22000842

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00415T TR200000415T2 (tr) 1997-08-15 1998-08-13 Prostat kanserinin tedavi edilmesi için birleşimler.

Country Status (23)

Country Link
US (1) US5985877A (tr)
EP (1) EP1011648B2 (tr)
JP (1) JP2001515032A (tr)
KR (1) KR100612161B1 (tr)
CN (1) CN1147317C (tr)
AT (1) ATE208210T1 (tr)
AU (1) AU737092B2 (tr)
BR (1) BR9812122A (tr)
CA (1) CA2299471C (tr)
CZ (1) CZ297198B6 (tr)
DE (1) DE69802422T3 (tr)
DK (1) DK1011648T4 (tr)
EA (1) EA002525B1 (tr)
ES (1) ES2163293T5 (tr)
HK (1) HK1028565A1 (tr)
HU (1) HUP0003194A3 (tr)
NO (1) NO325526B1 (tr)
NZ (2) NZ502646A (tr)
PL (1) PL193375B1 (tr)
PT (1) PT1011648E (tr)
TR (1) TR200000415T2 (tr)
UA (1) UA61970C2 (tr)
WO (1) WO1999008668A2 (tr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6004999A (en) * 1998-10-08 2000-04-26 Takeda Chemical Industries Ltd. Agents for retarding change of hormone-dependent cancer into hormone-independentcancer
GB0007371D0 (en) * 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US20020169154A1 (en) * 2001-04-04 2002-11-14 Cephalon, Inc. Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents
PL363322A1 (en) * 2001-05-08 2004-11-15 Merck Patent Gmbh Combination therapy using anti-egfr antibodies and anti-hormonal agents
SE0101697D0 (sv) * 2001-05-14 2001-05-14 Astrazeneca Ab Pharmaceutical combination
IL144583A0 (en) 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
CA2458452C (en) * 2001-08-10 2011-04-19 Takeda Chemical Industries, Ltd. Gnrh agonist combination drugs
AU2002331720B2 (en) * 2001-08-24 2007-10-11 Johns Hopkins University Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 il?9 항체 및 그의 용도
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
US20050048617A1 (en) 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
AU2006257664B2 (en) 2005-06-14 2013-01-10 Protox Therapeutics Incorporated Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
EP1893647A2 (en) 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
CA2641310C (en) * 2006-02-03 2013-08-20 Imclone Systems Incorporated Igf-ir antagonists as adjuvants for treatment of prostate cancer
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
RU2491094C2 (ru) 2007-03-30 2013-08-27 Медиммун, Ллк Препарат антитела
US20090130195A1 (en) 2007-10-17 2009-05-21 Mildred Acevedo-Duncan Prostate carcinogenesis predictor
EP2668210B1 (en) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
AU2013295848B2 (en) 2012-07-25 2018-05-24 Celldex Therapeutics, Inc. Anti-KIT antibodies and uses thereof
US20150231240A1 (en) 2012-10-09 2015-08-20 Igenica Biotherapeutics, Inc. Anti-c16orf54 antibodies and methods of use thereof
AU2014274660B2 (en) 2013-06-06 2019-05-16 Pierre Fabre Médicament Anti-C10orf54 antibodies and uses thereof
RS62189B1 (sr) 2013-08-26 2021-08-31 Biontech Research And Development Inc Nukleinske kiseline koje kodiraju humana antitela na sijalil-luis a
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA2950602C (en) 2014-06-04 2021-07-20 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside gd2
CN114230664A (zh) 2014-12-11 2022-03-25 皮埃尔法布雷医药公司 抗c10orf54抗体及其用途
DE112016001013T5 (de) 2015-03-03 2017-12-21 Kymab Limited Antikörper, verwendungen und verfahren
KR20180012299A (ko) 2015-05-29 2018-02-05 메모리얼 슬로안-케터링 캔서 센터 초소형 나노입자를 사용하여 페로토시스를 통해 영양분-결핍 암 세포의 세포 사멸을 유도하는 치료 방법
CN108925136B (zh) 2015-12-02 2022-02-01 斯特赛恩斯公司 特异于糖基化的btla(b和t淋巴细胞衰减因子)的抗体
CN109415437B (zh) 2015-12-02 2022-02-01 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP2020520953A (ja) 2017-05-25 2020-07-16 メモリアル スローン ケタリング キャンサー センター ジルコニウム−89で標識した超小型ナノ粒子およびその方法
AU2018277545A1 (en) 2017-05-31 2019-12-19 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
CA3065301A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
RU2667906C1 (ru) * 2017-09-11 2018-09-25 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Производное класса N-гликозидов индоло[2,3-а]пирроло[3,4-с]карбазол-5,7-дионов - N-{ 12-(β-D-ксилопиранозил)-5,7-диоксо-индоло[2,3-а]пирроло[3,4-с] карбазол-6-ил} пиридин-2-карбоксамид, обладающее цитотоксической и противоопухолевой активностью
CN111630069B (zh) 2017-10-13 2024-05-31 勃林格殷格翰国际有限公司 针对Thomsen-nouvelle(Tn)抗原的人抗体
BR112021000934A2 (pt) 2018-07-20 2021-04-27 Pierre Fabre Medicament receptor para vista

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
DE3752123T2 (de) 1987-03-09 1998-05-14 Kyowa Hakko Kogyo Kk Derivate des physiologisch aktiven mittels k-252
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
KR100201343B1 (ko) * 1993-05-28 1999-06-15 바바라 에스 쉴버그 인돌로카르바졸 유도체들의 전립선의 병적상태치료에의 용도
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
SE506019C2 (sv) * 1994-05-17 1997-11-03 Forskarpatent I Linkoeping Ab Ljuskälla av konjugerade polymerer med spänningsstyrd färg samt metod för tillverkning av ljuskällan
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5594009A (en) 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5650407A (en) 1995-04-05 1997-07-22 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5659407A (en) * 1995-06-06 1997-08-19 Apple Computer, Inc. Method and system for rendering achromatic image data for image output devices
DE69736642T2 (de) 1996-07-19 2007-09-20 Takeda Pharmaceutical Co. Ltd. Heterocyclische Verbindungen, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
HK1028565A1 (en) 2001-02-23
PL193375B1 (pl) 2007-02-28
KR100612161B1 (ko) 2006-08-14
CA2299471A1 (en) 1999-02-25
ATE208210T1 (de) 2001-11-15
KR20010022878A (ko) 2001-03-26
EA002525B1 (ru) 2002-06-27
CZ2000469A3 (cs) 2001-08-15
NO20000732L (no) 2000-03-28
HUP0003194A2 (hu) 2001-07-30
CA2299471C (en) 2007-12-18
NO20000732D0 (no) 2000-02-14
AU9019298A (en) 1999-03-08
PT1011648E (pt) 2002-03-28
CN1147317C (zh) 2004-04-28
HUP0003194A3 (en) 2003-03-28
NZ517497A (en) 2004-11-26
WO1999008668A3 (en) 1999-04-15
DK1011648T4 (da) 2005-10-24
JP2001515032A (ja) 2001-09-18
DE69802422D1 (de) 2001-12-13
EP1011648B2 (en) 2005-07-20
WO1999008668A2 (en) 1999-02-25
EP1011648A2 (en) 2000-06-28
DE69802422T3 (de) 2005-12-29
AU737092B2 (en) 2001-08-09
CN1268061A (zh) 2000-09-27
US5985877A (en) 1999-11-16
PL338885A1 (en) 2000-11-20
DE69802422T2 (de) 2002-07-11
ES2163293T5 (es) 2006-01-16
BR9812122A (pt) 2000-07-18
UA61970C2 (en) 2003-12-15
DK1011648T3 (da) 2001-12-27
EA200000220A1 (ru) 2000-10-30
CZ297198B6 (cs) 2006-09-13
EP1011648B1 (en) 2001-11-07
ES2163293T3 (es) 2002-01-16
NZ502646A (en) 2002-04-26
NO325526B1 (no) 2008-06-02

Similar Documents

Publication Publication Date Title
TR200000415T2 (tr) Prostat kanserinin tedavi edilmesi için birleşimler.
ATE399007T1 (de) Raf kinase hemmer
MXPA01013395A (es) Tratamiento de cancer de prostata con anticuerpos anti-erbb2.
NO985652L (no) Anvendelse av naaladaseinhibitorer ved behandling av kreft
ATE368466T1 (de) Androgensyntheseinhibitoren
AU2209800A (en) Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia
DE69815313T2 (de) Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie
NO994330D0 (no) Metode for behandling av en tumor
NO20003848D0 (no) FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
BR9917113A (pt) Agente para tratar de distúrbio de função de células visuais compreendendo um inibidor de interleucina 2, seu método de tratamento e uso
WO2000004153A3 (en) Repression of cell transformation with human pea3
EA199800058A1 (ru) Способ лечения доброкачественной гиперплазии предстательной железы, лекарственная форма для лечения доброкачественной гиперплазии, содержащая агонист мелатонина
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.